NCT01959698View on ClinicalTrials.gov

Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

April 17, 2014

Primary Completion Date

June 1, 2020

Study Completion Date

December 1, 2025

Conditions
CD20 PositiveRecurrent Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell LymphomaStage I Diffuse Large B-Cell LymphomaStage II Diffuse Large B-Cell LymphomaStage III Diffuse Large B-Cell LymphomaStage IV Diffuse Large B-Cell Lymphoma
Interventions
DRUG

Carboplatin

Given IV

DRUG

Carfilzomib

Given IV

DRUG

Etoposide

Given IV

DRUG

Ifosfamide

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

BIOLOGICAL

Rituximab

Given IV

Trial Locations (1)

14263

Roswell Park Cancer Institute, Buffalo

Sponsors

Collaborators (1)

Amgen
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Amgen

INDUSTRY

lead

Roswell Park Cancer Institute

OTHER

NCT01959698 - Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma | Biotech Hunter | Biotech Hunter